Skip to main navigation
Ascendis Pharma Logo
  • Overview
  • Events & Presentations
  • News Releases
    • For Global Media Only
    • For U.S. Media Only
  • Corporate Governance
    • Corporate Governance Documents & Charters
    • Leadership
    • Committee Composition
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Financial & Filings
    • Quarterly Reports
    • SEC Filings
    • Annual General Meeting
    • Extraordinary General Meeting
      • Sept. 9, 2022 EGM
      • Nov. 18, 2021 EGM

Events & Presentations

Events & Presentations

Upcoming Events

More events are coming soon.

Past Events

March 02, 2026 at 11:10 AM EST
TD Cowen 46th Annual Health Care Conference
Click Here for Webcast
March 02, 2026 at 8:00 AM EST
YUVIWEL FDA Approval Call
Click Here for Webcast

Presentations

August 12, 2024
YORVIPATH® FDA Approval Slide Presentation
May 14, 2024
ECE 2024: 2-year results from the Phase 3 PaTHway Trial
January 7, 2024
42nd Annual J.P. Morgan Healthcare Conference Presentation
October 26, 2023
Ascendis Pharma 2023 ESMO Presentation
September 5, 2023
New TransCon™ Carrier Platform
June 17, 2023
52-Week Results from Open-Label Extension of the Phase 3 PaTHway Trial
May 31, 2023
Ascendis Pharma 2023 Oncology Program Update
January 8, 2023
41st Annual J.P. Morgan Healthcare Conference Presentation
November 13, 2022
TransCon™ CNP ACcomplisH Trial Topline Results
November 11, 2022
TransCon™ TLR7/8 Agonist Initial Results from Dose Escalation Portion of transcendIT-101 Trial

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page next ›
  • Last page last »

Shareholder Tools

RSS Feeds
Email Alerts
IR Contact

Footer Corporate Menu

  • TransCon
  • About us
  • Pipeline
  • Patients
  • Investors & News
  • Contact Us

Footer Copyrights Menu

  • Privacy Policy
  • Terms of Use
Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group
© March 2026 Ascendis Pharma